Montelucaste Sandoz (Montelukast)

Montelukast, the active ingredient in Montelucaste Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral administration. It helps control chronic asthma, prevent exercise‑induced bronchoconstriction, and relieve symptoms of seasonal or perennial allergic rhinitis in both adult and pediatric patients. The medication works by blocking cysteinyl leukotriene receptors in the airways, reducing inflammation and narrowing of the bronchial tubes.

GNH USA supplies Montelucaste Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation and allergic symptoms.

- Asthma: provides maintenance therapy to reduce the frequency and severity of asthma attacks. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Abdominal pain - Cough - Upper respiratory tract infection

Serious or Rare Side Effects: - Neuropsychiatric events (e.g., agitation, depression, suicidal thoughts) - Allergic reactions (e.g., rash, angioedema, anaphylaxis) - Hepatotoxicity (elevated liver enzymes, hepatitis)

When prescribing Montelukast, clinicians should consider several safety measures.

- Assess asthma control before initiating: ensure the patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric symptoms: report mood changes, depression or suicidal thoughts. - Use with caution in hepatic impairment: adjust if liver function is abnormal. - Avoid in patients with known hypersensitivity to montelukast or formulation components. - Pregnancy and lactation: discuss risks with the prescriber; data are limited. - Store at ambient temperature: keep below 25 °C, retain in the original container, protect from moisture and light.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: induces metabolism, lowering efficacy. - Ketoconazole: may increase montelukast levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilation, monitor clinical response. - Antidepressants (SSRIs): possible increase in neuropsychiatric side effects.